Tentative deal reached to end DHL Express lockout
Video
The union says a tentative agreement has been reached to end the DHL Express lockout. Workers have been off the job since June 8.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
42 minutes ago
- Globe and Mail
Is The Trade Desk Stock Worth the Hype? Here's What Our Experts Think.
Explore the exciting world of The Trade Desk (NASDAQ: TTD) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of May 14, 2025. The video was published on Jun. 25, 2025. Should you invest $1,000 in The Trade Desk right now? Before you buy stock in The Trade Desk, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and The Trade Desk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor 's total average return is809% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Globe and Mail
an hour ago
- Globe and Mail
Non-Tech Markets Lose Steam; Nasdaq Approaches Record High
Markets look to have grown fairly exhausted today, sliding from the green to red during the morning hours and closing flat-to-down (aside from the Nasdaq, where the tech trade remains healthy) and reaching the closing bell at lackluster levels. The Dow slipped 106 points, -0.25%, while the S&P 500 was exactly unched — 0.0% — on the day. The Nasdaq gained +61 points, +0.31%, while the small-cap Russell 2000 closed at session lows: -0.99%. The morning-hours catalyst may have been Fed Chair Jerome Powell today, appearing before the Senate Banking Committee to discuss the possibility of cutting interest rates. Yesterday, Powell energized markets somewhat when he told the House Financial Services that the Fed could cut rates 'sooner than later,' but today he predicted inflation coming from tariff policy in the coming months. 'Someone has to pay,' he told the panel. Yet the Nasdaq is approaching fresh all-time highs not seen since February, as the AI-trade narrative has kept top tech stocks buoyant. Take NVIDIA NVDA, for instance, which is up nearly +64% just since its early April lows during trade war fears before reciprocal tariffs were paused for 90 days. Shares are now at record highs as AI investment reported by companies in various industries are engaged in the technological buildout for which NVIDIA leads in component-building. Micron Beats & Raises for Q3 Fiscal Q3 earnings were released after today's close from data storage giant Micron MU. This company is a good example of how AI investment bolsters companies in this realm of the tech space, as well. Earnings of $1.68 per share outpaced the Zacks consensus by 9 cents, up a whopping +171% year over year. Revenues of $9.30 billion easily surpassed the $8.84 billion analysts were looking for. Bot only that, but Micron raised guidance fairly significantly for its fiscal Q4: earnings of between $2.35-2.65 per share is well ahead of the $2.02 consensus, with between $10.4-11.0 billion in revenues far beyond the $9.9 billion previously projected. As such, expect this Zacks Rank #3 (Hold)-based stock to ratchet up a bit in the days to come. Shares had already been up +51.2% year to date, and are up another +4% in late trading. (You can see the full Zacks Earnings Calendar here. What to Expect from the Stock Market Thursday We have a full plate of economic reports before tomorrow's opening bell, with a new Trade Balance in Goods, Retail/Wholesale Inventories, Durable Goods and Pending Home Sales all accompanying the second revision to Q1 GDP. But what we'll be paying extra close attention to tomorrow are the Weekly Jobless Claims. Initial Jobless Claims touched 250K a couple weeks ago, second only to the 259K reported back in early October of last year (which appears like an anomalous blip on the screen). They came back down to 245K in last week's report, and we hope to see this continue downward. Continuing Claims, reported a week in arrears from new claims, clearly look they are breaking out to new levels. After spending much of 2025 chopping back and forth between 1.85-1.9 million, the past two weeks have shot up to a new range around 1.95 million. If this comes back down we won't make too much of it. But touching that 2 million level on longer-term jobless claims will have a psychological effect on markets — and perhaps the Fed as well. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Micron Technology, Inc. (MU): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Why Nektar Therapeutics Stock Was Red-Hot Today
The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering excellent news from the lab, the company's shares leaped 19% higher on a significant analyst price target change. A clear buy, says analyst Well before market open, H.C. Wainwright's Arthur He poured some rocket fuel into his Nektar price target, setting it anew at $120 per share. That's far above his previous level, which was a mere $6.50. In making the change, he left his buy recommendation intact. In what's hardly a surprising development, He's adjustment was due to the positive results in the latest completed clinical trial for Nektar's eczema drug rezpegaldesleukin. The study put the medicine through its paces for the treatment of moderate-to-severe atopic dermatitis (AD), a form of eczema. In the analyst's view, it did well enough to become a top drug in the treatment of the affliction. On Tuesday, the biotech announced, no doubt with immense satisfaction, that rezpegaldesleukin met all of its primary and secondary endpoints in the phase 2b trial. After 16 weeks of treatment with the subcutaneous drug, patients demonstrated a 53% to 61% improvement in symptoms when measured with an eczema index. This compared very favorably to 31% for patients taking a placebo. Vast potential This easily makes Nektar's drug the success of the week in the biotech world. As pointed out by He, Rezpegaldesleukin clearly has potential to treat the many people who suffer from AD. As such, the progress of the drug -- and its developer -- will be exciting to watch going forward. Should you invest $1,000 in Nektar Therapeutics right now? Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor 's total average return is809% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
